Drug Markets/Tocilizumab-Aazg

Tocilizumab-Aazg

2 NDCs across 1 manufacturer|0 Generic,2 Brand

Tocilizumab-Aazg is used to treat juvenile arthritis, rheumatoid arthritis, cytokine release syndrome and giant cell arteritis, per the National Library of Medicine's MED-RT classification.

▸ More about this market

In 2024, Medicare Part D spent $3 million on Tocilizumab-Aazg across 1,563 claims for 444 beneficiaries.

Tocilizumab-Aazg is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $821.00 to $821.00 per ML. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

2

0G / 2B

Manufacturers

1

competing in market

Price Spread

$821.00 – $821.00

per ML

7d Activity

20 flat

avg +0.0% WoW · of 2 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing TOCILIZUMAB-AAZG

Drug Portfolio

2 NDCs total, 2 shown

Drug Price 7d Change
TYENNE 162 MG/0.9 ML AUTOINJCT
$820.9968
per ML
+0.04%
TYENNE 162 MG/0.9 ML AUTOINJCT
$820.9968
per ML
+0.04%

Frequently Asked Questions

What is Tocilizumab-Aazg used to treat?

Tocilizumab-Aazg is used to treat juvenile arthritis, rheumatoid arthritis, cytokine release syndrome and giant cell arteritis, per the National Library of Medicine's MED-RT classification.

How much does Medicare spend on Tocilizumab-Aazg?

In 2024, Medicare Part D spent $3 million on Tocilizumab-Aazg across 1,563 claims for 444 beneficiaries.

How many Tocilizumab-Aazg products are on the market?

The Tocilizumab-Aazg drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.

What is the price range for Tocilizumab-Aazg?

NADAC reference prices for Tocilizumab-Aazg range from $820.9968 to $820.9968 per ML.

Which manufacturers make Tocilizumab-Aazg?

1 manufacturer lists Tocilizumab-Aazg in NADAC. Ranked by number of NDCs, the largest are Fresenius Kabi USA, LLC (2).

How has the price of Tocilizumab-Aazg changed recently?

Over the past 7 days, 2 Tocilizumab-Aazg NDCs rose and 0 fell, with a market-wide average change of +0.0%.